• Trial Talks Podcast
  • COVID-19
  • Blog
  • Client Login

Therapeutic Spotlight: Oncology

Infographic

The Trial

A recent six-year, open-label, phase I/II interventional study investigated the safety, pharmacokinetics, and tumor response in B cell lymphoma patients. Those building the study found it easy to leverage Medrio’s do-it-yourself mid-study changes and drag-and-drop query programming, avoiding unnecessary delays and improving data quality.

Study Stats

Team members building the study found it easy to leverage Medrio’s do-it-yourself mid-study changes and drag-and-drop query programming, avoiding unnecessary delays and improving data quality.

0+

Mid-study Changes

0

Queries Programmed

0+

Million Datapoints

0+

Users

0+

Queries Raised/Resolved

75+

Mid-study Changes

300

Queries Programmed

1400000+

Million Datapoints

300+

Users

15000+

Queries Raised/Resolved

The Outcome: Publications indicate the study demonstrated no dose limiting toxicity and a high progression-free survival rate at 3 years.